|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product | |||||
| Contribution | |||||
| Total revenue | |||||
| Costs and expenses: | |||||
| Cost of product revenue | |||||
| Product | |||||
| Total cost of product revenue | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Impairment of property and equipment | |||||
| Total costs and expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest income | |||||
| Interest expense | |||||
| Change in fair value of derivative instrument | |||||
| Interest expense to related party | |||||
| Change in fair value of derivative related to Term Loan with related party | |||||
| Change in fair value of warrant liabilities | |||||
| Other, net | |||||
| Other expense | |||||
| Other losses | |||||
| Total other income (expense) | |||||
| Net loss | |||||
| Net loss per share — basic and diluted | |||||
| Weighted-average number of common shares used in computing net loss per share — basic and diluted | |||||
| Net unrealized gain on marketable securities arising during the period | |||||
| Net realized gain on marketable securities included in net loss | |||||
| Total other comprehensive (loss) gain, net of taxes | |||||
| Total other comprehensive income, net of taxes | |||||
| Comprehensive loss | |||||
| Deemed dividend on Series A Redeemable Convertible Preferred Stock | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share - basic | |||||
| Net loss per share - diluted | |||||
| Weighted-average number of common shares used in computing net loss per share - basic | |||||
| Weighted-average number of common shares used in computing net loss per share - diluted | |||||
Loading...